NOVUS THERAPEUTICS INC's ticker is NVUS and the CUSIP is 67011N105. A total of 21 filers reported holding NOVUS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $273,000 | -57.5% | 270,000 | +69.1% | 0.03% | -62.5% |
| Q1 2019 | $643,000 | +233.2% | 159,705 | +32.8% | 0.08% | +196.3% |
| Q4 2018 | $193,000 | -8.5% | 120,219 | +167.2% | 0.03% | +8.0% |
| Q3 2018 | $211,000 | +197.2% | 45,000 | +345.9% | 0.02% | +177.8% |
| Q2 2018 | $71,000 | – | 10,092 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,537,110 | $4,059,000 | 0.08% |
| Boxer Capital, LLC | 324,383 | $519,000 | 0.06% |
| B. Riley Wealth Advisors, Inc. | 120,219 | $193,000 | 0.03% |
| CARY STREET PARTNERS INVESTMENT ADVISORY LLC | 10,600 | $22,000 | 0.02% |
| Sequoia Financial Advisors, LLC | 22,500 | $36,000 | 0.00% |
| VANGUARD GROUP INC | 42,403 | $68,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 10,944 | $18,000 | 0.00% |
| UBS Group AG | 1,061 | $2,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 23,424 | $36,000 | 0.00% |